Month: May 2020

Continued progress on treatment of TC-210 patients with interim update from Phase 1 portion of Phase 1/2 clinical trial anticipated in mid-2020Continued progress of TC-110 with initiation of leading clinical sites participating in Phase 1/2 clinical trial that include Sarah Cannon Research Institute and Colorado Blood Cancer InstituteTC-110 granted orphan drug designation for the treatment of acute lymphoblastic leukemiaNomination of third mono TRuC program targeting CD70 with anticipated IND filing in 1H21Two new appointments to the Board of Directors: immuno-oncology pioneer Dr. Axel Hoos and veteran finance executive Stephen WebsterCash position of $141M provides sufficient runway into 2022CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing...

–Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 —— Raised $51.6 million through a private placement with new and existing investors —DUBLIN, Ireland and CHICAGO, May 14, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2020.“During this challenging time, it is more important than ever to avoid hospitalization. We believe sulopenem, as potentially the first and only oral and IV penem antibiotic, will provide physicians the confidence and flexibility to treat their patients in a community...

Modern FLEXITY trams have achieved authorization to operate in the Düsseldorf metropolitan areaThe new generation of FLEXITY trams are energy efficient and offer additional safety and comfort for passengersBERLIN, May 14, 2020 (GLOBE NEWSWIRE) —Global mobility solution provider Bombardier Transportation announced today that it has received authorization for their BOMBARDIER FLEXITY trams to begin operation in the Düsseldorf and Duisburg network. This means that Rheinbahn can now start using the trams for passenger service within the Düsseldorf metropolitan area in Germany.“We are delighted to have reached this important commissioning milestone. This will support our efforts to condense tram traffic cycles in Düsseldorf, planned for this year. With the new HF6 vehicles for the Rheinbahn, we are offering our passengers more services...

Moderne FLEXITY Straßenbahnen können im Fahrgastbetrieb in der Rheinmetropole eingesetzt werdenFLEXITY Trams der neuen Generation sind energiesparend und bieten mehr Sicherheit und Komfort für die FahrgästeBERLIN, May 14, 2020 (GLOBE NEWSWIRE) —A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/dbb4fd82-e97e-4b74-bb0a-c864ca423641/deDer globale Mobilitätsanbieter Bombardier Transportation gab heute bekannt, dass die Zulassung für den Einsatz der BOMBARDIER FLEXITY-Hochflurstraßenbahnen im Fahrgastbetrieb erteilt wurde. Das bedeutet, dass die Straßenbahnen ab sofort im Netz der Rheinbahn in Düsseldorf und Duisburg eingesetzt werden können.Michael Richarz, Vorstand Technik und Betrieb bei der Rheinbahn AG, sagt: „Wir freuen uns, dass wir einen wichtigen Meilenstein bei der Inbetriebnahme...

ROCHESTER HILLS, Michigan, May 14, 2020 (GLOBE NEWSWIRE) — InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2020.First Quarter Highlights:Net revenues for the first quarter of 2020 were $21.6 million, an increase of 18% from the same prior year period.Gross profit for the first quarter of 2020 was $12.7 million, an increase of 22% from the same prior year period.Gross margin for the first quarter of 2020 was 58.8%, an increase of 2.0% from the same period prior year period.Net loss was $0.4 million, or $(0.02) per diluted share, an improvement of 57% compared to the net loss of $1.0...

BARRIE, Ontario, May 14, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp., (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has signed a multi-faceted strategic manufacturing agreement with Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) (“Avicanna”) involving licensed production, domestic and international distribution and intellectual property licensing. Avicanna is a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products.Under the agreement, which has an initial three-year term, MediPharm Labs will use the specialized contract manufacturing capabilities...

Reference is made to the stock exchange notification published by Electromagnetic Geoservices ASA (“EMGS” or the “Company”) on 2 December 2019, wherein it was announced that Mr Anders Eimstad had been appointed interim CFO of the Company.EMGS is pleased to announce that the appointment has now been made permanent.Contact Anders Eimstad, Chief Financial Officer, +47 948 25 836This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

– Initiating Clinical Studies of KB109 in Outpatients with Mild-to-Moderate COVID-19; Data Anticipated in Q4 2020 –– Expanding Work in Immune-Mediated and Inflammatory Diseases; Data from New Clinical Study in Ulcerative Colitis Expected in Mid-2021 –– Conference Call Scheduled for 8:30 a.m. ET Today –LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today provided a corporate update and announced financial results for the first quarter 2020. “The COVID-19 pandemic is having an unprecedented impact on the global healthcare system. We continue to adapt our work to prioritize the safety of our employees, as well as patients...

New data and pathological findings on BriaCell’s lead candidate, Bria-IMT™, to be Highlighted at ASCO 2020 in a Poster PresentationBERKELEY, Calif. and VANCOUVER, British Columbia, May 14, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the publication of its abstract in the ASCO Meeting Library — available in the Journal of Clinical Oncology by May 26, 2020. The Company will present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and...

– Top-Line Data from Study of Approximately 350 Patients Expected in Q4 2020 –            – Second Clinical Study Expected to Initiate Shortly with Similar Design and Additional Microbiome Analysis –LEXINGTON, Mass., May 14, 2020 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health today announced the initiation of a controlled clinical study evaluating Microbiome Metabolic Therapy (MMT) candidate KB109 added to Supportive Self-Care (SSC) for outpatients who are positive for SARs-Cov-2 infection with mild-to-moderate COVID-19.“The burden of the COVID-19 pandemic on patients and healthcare facilities is vast, and there remains a need for interventional studies evaluating...